CEUS - New Video!

Category: ICUS News

microbubbles-screenshot

 

 

 

 

 

 

 

ICUS has a new and exciting video that represents excellent promotion of CEUS imaging.

Aimed at the general public, the 2-minute video clip is due to be shown throughout December and January on American Airlines flights in that airline's in-flight, business TV entertainment.

While viewers will inevitably include those in the medical profession at all levels, the video is aimed at the 'person on the street', which of course also includes all those in healthcare management, administration and supply.  To view the video, click here.

FDA Approves Label Changes for Optison

Category: ICUS News

The FDA has approved label changes for GE Healthcare's ultrasound contrast agent Optison, removing contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection. Optison is the 1st contrast agent available in the U.S. to receive this label change, according to GE.

ICUS Co-President, Dr. Steven Feinstein commented:  “Up to one-third of our patients have known or suspected cardiac shunts and, thanks to this important FDA decision, they too will now have access to ultrasound contrast agents, which offer an inexpensive and radiation-free option for diagnostic imaging.”  He added,  “The International Contrast Ultrasound Society applauds the FDA for its decision, and believes it will benefit individual patients as well as our healthcare delivery system.”

Click here to read the full story

FDA Approval of New Liver Imaging Agent in the US

Category: ICUS News

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., has announced  that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
 
LUMASON, known globally as SonoVue®, was approved by the FDA ion October 2014 for use in adults with suboptimal echocardiograms.  LUMASON is now the first ultrasound contrast agent to obtain FDA approval for use in liver imaging, to improve the sensitivity and specificity of ultrasonography for the differentiation between malignant and benign focal hepatic lesions. This approval also makes LUMASON the first ultrasound contrast agent approved for use in the pediatric population.
 
Click here for ICUS media release.

SonoVue Approved in Mexico!

Category: ICUS News

ICUS is pleased to note that the Mexican Federal Commission for Protection Against Sanitary Risk (COFEPRIS) has approved the contrast agent SonoVue in Mexico for use in echocardiography and Doppler ultrasonography. SonoVue is produced by Bracco and will be marketed in Mexico by Justesa Imagen Mexicana, S.A. de C.V.
 
ICUS applauds this action. We have long advocated for broader acceptance and appropriate use of ultrasound contrast agents, which have strong safety profiles and reduce overall health care costs without exposing patients to ionizing radiation.

ICUS Announces New Board Member for Sonography

Category: ICUS News

Beverly Gorman, RDCS
IAC Director of Accreditation - Echocardiography
 
ICUS is pleased to announce the election of its newest Board member, Beverly Gorman, RDCS.  She will serve in a newly created position as the first Board member representing the field of sonography.  Click here to read bio

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home Features Layout ICUS News